Leckman Patricia sold $127K of ILMN

Leckman Patricia (SVP, Chief People Officer) sold 784 shares of ILLUMINA, INC. (ILMN) at an average of $162.08 ($160.66–$163.02, $0.13M total) across 3 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leckman Patricia
Published Jun 4, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock materially.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing could drive the sale.

Relevance 3/10Novelty 3/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

SVP Chief People Officer sold 784 shares for $127K via a 10b5-1 plan on 2026-06-02.

Expected impact

minor pressure as market prices in the sale

Evidence & confidence

The transaction size is modest relative to market cap, but insider selling can be viewed as a slight negative signal.

Market effects

Minimal impact on the broader semiconductor sector.

No significant regional effect.

Limited relevance globally.

Counterpoint

The sale may be routine and unrelated to company fundamentals.

Key entities

  • Patricia Leckman

    SVP, Chief People Officer at Illumina

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.